HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, A. D. Articles by Shah, S. N. Search for Related Content PubMed PubMed Citation Articles by Smith, A. D. Articles by Shah, S. N. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT

¹ All authors: Imaging Institute, Cleveland Clinic, 9500 Euclid Ave., HB6, Cleveland, OH 44195.

OBJECTIVE. The aim of this study was to improve response assessment in patients with metastatic renal cell carcinoma (RCC) on antiangiogenic targeted therapy by evaluating changes in both tumor size and attenuation and by detecting unique patterns of contrast enhancement on contrast-enhanced CT (CECT).

MATERIALS AND METHODS. Tumor long-axis measurements and volumetric mean tumor attenuation of target lesions on CECT images were correlated with time to progression in 53 patients with metastatic clear cell RCC treated with first-line sorafenib or sunitinib. The frequencies of specific patterns of tumor progression were assessed. The data were used to develop new imaging criteria, the size and attenuation CT (SACT) criteria. CECT findings were evaluated using the SACT criteria, Response Evaluation Criteria in Solid Tumors (RECIST), and modified Choi criteria, and the Kaplan-Meier method was used to estimate survival functions.

RESULTS. One or more target metastatic lesions had decreased attenuation of 40 HU in 59% of patients with progression-free survival of > 250 days (n = 44) after initiating targeted therapy; 0% of patients with earlier disease progression (n = 9) had this finding. A favorable response based on SACT criteria had a sensitivity of 75% and specificity of 100% for identifying patients with progression-free survival of > 250 days, versus 16% and 100%, respectively, for RECIST and 93% and 44% for the modified Choi criteria.

CONCLUSION. Objectively measuring changes in both tumor size and attenuation on the first CECT study after initiating targeted therapy for metastatic RCC markedly improves response assessment. Distinct patterns of disease recurrence are seen in patients with metastatic RCC on targeted therapy.

Keywords: contrast-enhanced CT • metastatic renal cell carcinoma • response assessment • tumor attenuation • tumor recurrence

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. D. Smith, S. N. Shah, B. I. Rini, M. L. Lieber, and E. M. Remer Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy Am. J. Roentgenol., June 1, 2010; 194(6): 1470 - 1478. [Abstract] [Full Text] [PDF]

				B. I. Rini New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance Clin. Cancer Res., March 1, 2010; 16(5): 1348 - 1354. [Abstract] [Full Text] [PDF]